Trial Profile

Phase II Study of BKM120 in Men With Metastatic Castration-Resistant Prostate Cancer.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Buparlisib (Primary) ; Enzalutamide
Indications Prostate cancer
Focus Therapeutic Use

Most Recent Events

01 Aug 2017 According to results published in the European Journal of Cancer, concurrent buparlisib and enzalutamide at 160 mg once daily was permitted through a protocol amendment in order to test the efficacy of combined pathway inhibition in men with mCRPC progressing on enzalutamide, the use of concurrent enzalutamide was not randomized but rather offered to patients progressing on enzalutamide at entry.
01 Aug 2017 Results published in the European Journal of Cancer.
22 Feb 2017 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com